These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

589 related items for PubMed ID: 10192210

  • 1. Progression of neurofibrillary changes and PHF-tau in end-stage Alzheimer's disease is different from plaque and cortical microglial pathology.
    Thal DR, Arendt T, Waldmann G, Holzer M, Zedlick D, Rüb U, Schober R.
    Neurobiol Aging; 1998; 19(6):517-25. PubMed ID: 10192210
    [Abstract] [Full Text] [Related]

  • 2. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
    Koss DJ, Jones G, Cranston A, Gardner H, Kanaan NM, Platt B.
    Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
    [Abstract] [Full Text] [Related]

  • 3. [F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging.
    Marquié M, Siao Tick Chong M, Antón-Fernández A, Verwer EE, Sáez-Calveras N, Meltzer AC, Ramanan P, Amaral AC, Gonzalez J, Normandin MD, Frosch MP, Gómez-Isla T.
    Acta Neuropathol; 2017 Oct; 134(4):619-628. PubMed ID: 28612291
    [Abstract] [Full Text] [Related]

  • 4. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease.
    Streit WJ, Braak H, Xue QS, Bechmann I.
    Acta Neuropathol; 2009 Oct; 118(4):475-85. PubMed ID: 19513731
    [Abstract] [Full Text] [Related]

  • 5. Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques.
    Monsell SE, Kukull WA, Roher AE, Maarouf CL, Serrano G, Beach TG, Caselli RJ, Montine TJ, Reiman EM.
    JAMA Neurol; 2015 Oct; 72(10):1124-31. PubMed ID: 26302353
    [Abstract] [Full Text] [Related]

  • 6. Enhanced microglial dynamics and a paucity of tau seeding in the amyloid plaque microenvironment contribute to cognitive resilience in Alzheimer's disease.
    Jury-Garfe N, Redding-Ochoa J, You Y, Martínez P, Karahan H, Chimal-Juárez E, Johnson TS, Zhang J, Resnick S, Kim J, Troncoso JC, Lasagna-Reeves CA.
    Acta Neuropathol; 2024 Aug 05; 148(1):15. PubMed ID: 39102080
    [Abstract] [Full Text] [Related]

  • 7. Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology.
    Perez-Nievas BG, Stein TD, Tai HC, Dols-Icardo O, Scotton TC, Barroeta-Espar I, Fernandez-Carballo L, de Munain EL, Perez J, Marquie M, Serrano-Pozo A, Frosch MP, Lowe V, Parisi JE, Petersen RC, Ikonomovic MD, López OL, Klunk W, Hyman BT, Gómez-Isla T.
    Brain; 2013 Aug 05; 136(Pt 8):2510-26. PubMed ID: 23824488
    [Abstract] [Full Text] [Related]

  • 8. A Study of Amyloid-β and Phosphotau in Plaques and Neurons in the Hippocampus of Alzheimer's Disease Patients.
    Furcila D, DeFelipe J, Alonso-Nanclares L.
    J Alzheimers Dis; 2018 Aug 05; 64(2):417-435. PubMed ID: 29914033
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype.
    Berg L, McKeel DW, Miller JP, Storandt M, Rubin EH, Morris JC, Baty J, Coats M, Norton J, Goate AM, Price JL, Gearing M, Mirra SS, Saunders AM.
    Arch Neurol; 1998 Mar 05; 55(3):326-35. PubMed ID: 9520006
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.
    Serrano-Pozo A, William CM, Ferrer I, Uro-Coste E, Delisle MB, Maurage CA, Hock C, Nitsch RM, Masliah E, Growdon JH, Frosch MP, Hyman BT.
    Brain; 2010 May 05; 133(Pt 5):1312-27. PubMed ID: 20360050
    [Abstract] [Full Text] [Related]

  • 18. Review on Alzheimer's disease: Inhibition of amyloid beta and tau tangle formation.
    Ashrafian H, Zadeh EH, Khan RH.
    Int J Biol Macromol; 2021 Jan 15; 167():382-394. PubMed ID: 33278431
    [Abstract] [Full Text] [Related]

  • 19. Olfactory tau pathology in Alzheimer disease and mild cognitive impairment.
    Attems J, Jellinger KA.
    Clin Neuropathol; 2006 Jan 15; 25(6):265-71. PubMed ID: 17140156
    [Abstract] [Full Text] [Related]

  • 20. Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimer's pathology not α-synuclein pathology.
    Walker DG, Lue LF, Tang TM, Adler CH, Caviness JN, Sabbagh MN, Serrano GE, Sue LI, Beach TG.
    Neurobiol Aging; 2017 Jun 15; 54():175-186. PubMed ID: 28390825
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.